Differentiated Thyroid Cancer in Adolescents: Single Center Experience and Considerations for Surgical Management and Radioiodine Treatment
adolescents
prophylactic lymphadenectomy
Differentiated thyroid cancer
Journal
Journal of clinical research in pediatric endocrinology
ISSN: 1308-5735
Titre abrégé: J Clin Res Pediatr Endocrinol
Pays: Turkey
ID NLM: 101519456
Informations de publication
Date de publication:
23 08 2023
23 08 2023
Historique:
medline:
24
8
2023
entrez:
29
3
2023
pubmed:
30
3
2023
Statut:
ppublish
Résumé
Differentiated thyroid cancer (DTC) in adolescents rare but with a favorable outcome, despite higher rates of cervical lymph node and pulmonary metastasis compared to adults. The aim of this study was to critically evaluate treatment of adolescents with DTC at a single center. Patients receiving postoperative radioiodine treatment (RAIT) for DTC between 2005 and 2020 at our institution were screened to identify adolescents according to the World Health Organization definition (10-19 years of age). Demographics, clinico-pathological characteristics, treatment and outcome were analyzed. Among 1,897 DTC patients, 23 (1.3%) were adolescents with a median (range) age of 16 (10-18) years. The female to male ratio was 3.6:1. Sixty percent had classic papillary thyroid cancer, with follicular variant in 40%, which was higher than previously reported (15-25%) for this age group. pT-status was pT1 in 9 (39.2%), pT2 in 8 (34.8%), pT3 in 3 (13%) and pT4 in 3 (13%) patients. In 19 (82.6%) patients, central lymphadenectomy was performed and metastasis was seen in 57%. All patients received RAIT with initial activities of 1.2 (n=1, 4.3%), 2 (n=12, 52.2%) or 3.7 GBq (n=10, 43.5%). Eighteen (78.2%) patients were free of biochemical and radiologic disease at a median follow-up of 60.7 months. Second-line surgery for lymph node relapse was necessary in 3 (13%) cases. There was one disease-associated death. Despite high rates of metastasis, most patients were cured, and second-line surgery was rarely required. Further prospective studies are needed to determine whether less aggressive surgical management or omitting adjuvant RAIT are feasible in patients with limited stages at diagnosis.
Identifiants
pubmed: 36987773
doi: 10.4274/jcrpe.galenos.2023.2023-1-16
pmc: PMC10448561
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-263Références
J Clin Oncol. 2022 Apr 1;40(10):1081-1090
pubmed: 35015563
Endocr Rev. 2011 Dec;32(6):798-826
pubmed: 21880704
J Endocrinol Invest. 2016 Sep;39(9):1055-9
pubmed: 27129982
Nuklearmedizin. 2016 Jun 28;55(3):77-89
pubmed: 27350004
Thyroid. 2015 Jul;25(7):716-59
pubmed: 25900731
J Clin Oncol. 2022 May 1;40(13):1439-1449
pubmed: 35044839
Clin Endocrinol (Oxf). 2021 Jun;94(6):1004-1011
pubmed: 33484159
Endocrine. 2020 Dec;70(3):566-574
pubmed: 32533509
J Clin Endocrinol Metab. 2016 May;101(5):2031-9
pubmed: 26963949
Curr Pediatr Rev. 2016;12(4):247-252
pubmed: 27745544
Langenbecks Arch Surg. 2013 Mar;398(3):347-75
pubmed: 23456424
Eur Thyroid J. 2021 Jul;10(5):364-371
pubmed: 34540706
J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1308-e1309
pubmed: 34610121
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Thyroid. 2022 Feb;32(2):145-152
pubmed: 34549602
Eur J Endocrinol. 2020 Oct;183(4):P11-P18
pubmed: 32698145
Endocr Connect. 2021 Sep 20;10(9):1180-1188
pubmed: 34424854
Nuklearmedizin. 2007;46(5):224-31
pubmed: 17938759
J Clin Endocrinol Metab. 2022 Jan 1;107(1):e165-e177
pubmed: 34415989
Cancers (Basel). 2021 Jul 24;13(15):
pubmed: 34359632
Thyroid. 2022 Mar;32(3):236-244
pubmed: 34915753
Thyroid. 2014 Jul;24(7):1121-6
pubmed: 24731094